MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma

Background: Mucosal and acral melanoma respond worse to immune checkpoint inhibitors (ICI) than cutaneous melanoma. <i>MDM2/4</i> as well as <i>EGFR</i> amplifications are supposed to be associated with hyperprogression on ICI in diverse cancers. We therefore investigated the...

Full description

Bibliographic Details
Main Authors: Andrea Forschner, Franz-Joachim Hilke, Irina Bonzheim, Axel Gschwind, German Demidov, Teresa Amaral, Stephan Ossowski, Olaf Riess, Christopher Schroeder, Peter Martus, Bernhard Klumpp, Irene Gonzalez-Menendez, Claus Garbe, Heike Niessner, Tobias Sinnberg
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Cancers
Subjects:
hyperprogression
immune checkpoint inhibitors
acral melanoma
mucosal melanoma
mdm2
mdm4
egfr
Online Access:https://www.mdpi.com/2072-6694/12/3/540

Internet

https://www.mdpi.com/2072-6694/12/3/540

Similar Items